Weight regain after stopping a GLP-1 receptor agonist is the rule rather than the exception. A 2026 systematic review and meta-regression of six randomised trials found that about 60% of the weight lost on treatment returns within a year of stopping, following a predictable curve that then slows. Only one approach has been tested against placebo in a randomised trial and shown to limit that regain: continuing treatment, either at the full dose or at a reduced maintenance dose. Tapering schedules, supplements and specific diets circulating online have not been tested against stopping abruptly. This article is educational and is not medical advice; whether, when and how to stop is a decision for you and a licensed clinician. Advanced TRT Clinic is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.
What the Data Shows About Stopping
Until recently this question was answered trial by trial. In 2026 a team at the University of Cambridge pooled the evidence: a systematic review of 48 studies, with six randomised trials covering 3,236 participants entered into a nonlinear meta-regression that modelled the shape of the regain curve.
The findings were consistent. About 60% of treatment-induced weight loss returned within one year of stopping. The curve decelerated rather than running straight back to baseline, with a modelled half-life of 23 weeks — meaning roughly half of the eventual regain occurs in the first five months. Extrapolated forward, regain plateaued at 75.3% of the weight lost, which leaves approximately a quarter of the loss retained in the longer term. Trajectories were broadly similar across the different agents in the class.
Two caveats belong with those numbers. Follow-up in the included trials ran to 52 weeks, so the plateau beyond that point is extrapolated from the model rather than observed. And most of the included studies carried a moderate risk of bias.
Proportion of Lost Weight Regained After Stopping
All three values expressed the same way: as a share of the weight lost during treatment
| Pooled estimate at 1 year 6 randomised trials, n=3,236 |
60% | |
| STEP-1 extension at 1 year off treatment semaglutide, n=327 |
~67% | |
| Modelled long-term plateau extrapolated beyond observed data |
75% |
Figure 1. Group averages from trial populations. Individual trajectories vary considerably, and the plateau value is a model projection rather than an observed figure.
The individual trials behind that pooled figure tell a consistent story. In the STEP-1 trial extension, participants who had lost a mean of 17.3% of body weight over 68 weeks regained 11.6 percentage points in the year after both the medication and the structured lifestyle programme were withdrawn, finishing 5.6% below their original baseline. In SURMOUNT-4, participants switched to placebo after a 36-week lead-in regained 14.0% over the following year, while those who continued treatment lost a further 5.5%.
| Trial | What was withdrawn | What happened after |
|---|---|---|
| STEP-1 extension semaglutide, 1 year off treatment |
Medication and the lifestyle programme, both at week 68 | Regained 11.6 points of the 17.3% lost; net 5.6% below baseline at week 120. Cardiometabolic gains largely reverted |
| STEP-4 semaglutide, 48-week randomised phase |
Medication only, after a 20-week run-in | Placebo group gained 6.9%; continued group lost a further 7.9%. Difference 14.8 percentage points |
| SURMOUNT-4 tirzepatide, 52-week randomised phase |
Medication only, after a 36-week lead-in | Placebo group regained 14.0%; continued group lost a further 5.5% |
| SURMOUNT-MAINTAIN tirzepatide, 52-week maintenance phase |
Dose reduced to 5 mg, or withdrawn entirely, after 60 weeks | Reduced dose held 16.6% below baseline at week 112; placebo 9.9%; full dose 21.9% |
All four trials studied the products approved for chronic weight management: semaglutide 2.4 mg and tirzepatide at weight-management doses. Many people reading this will instead be taking a product approved for type 2 diabetes. Ozempic and Mounjaro carry that indication, and using either for weight reduction alone is off-label. The molecule is identical, so the pharmacology does not change — but the cost conversation usually does. Off-label use is generally harder to get covered and is typically excluded from manufacturer savings programmes, and cost is among the most common reasons people stop in the first place.
Why the Body Pushes Weight Back Up
Regain after stopping is not a failure of discipline, and framing it that way obscures what is actually happening.
These medications work by acting on appetite regulation and by slowing gastric emptying. Both effects depend on the drug being present. When it is withdrawn, appetite signalling returns to its prior pattern, the stomach empties at its usual rate, and the sensation of early fullness that made reduced intake manageable disappears over a few weeks.
A second mechanism compounds the first. A body at a lower weight requires fewer calories to maintain that weight than it did before. The intake that produced weight loss during treatment becomes the intake that produces weight gain once appetite returns, without anything about the person’s behaviour having changed.
This is why current clinical guidance characterises obesity as a chronic condition rather than an episode of treatment. The authors of the STEP-1 extension drew the same conclusion from their data: the physiological drivers persist after treatment ends, and sustaining the benefit generally requires sustaining something.
The One Strategy With Randomised Evidence Behind It
Most content on this subject describes habits, protocols and supplements. Almost none of it has been tested. One approach has.
SURMOUNT-MAINTAIN, published in The Lancet in 2026, was designed to answer whether a lower maintenance dose could hold weight that a full dose had achieved. 441 adults received open-label tirzepatide for 60 weeks; 378 were then randomised for a further 52 weeks to continue at their maximum tolerated dose of 10 mg or 15 mg, to step down to 5 mg, or to switch to placebo.
SURMOUNT-MAINTAIN: Weight Change From Baseline at Week 112
One trial, one population, three randomised maintenance strategies
| Continued at full dose 10 or 15 mg, n=140 |
−21.9% | |
| Stepped down to 5 mg n=144 |
−16.6% | |
| Switched to placebo n=94 |
−9.9% |
Figure 2. Model-based mean change from baseline at week 112. All three groups had lost weight on tirzepatide for 60 weeks before randomisation. Group averages, not individual predictions.
A second measure makes the difference concrete. Participants who regained at least half of the weight they had lost could receive rescue treatment. That threshold was reached by 8% of those who continued at full dose, 25% of those stepped down to 5 mg, and 67% of those switched to placebo.
The practical reading is that dose reduction is a genuine middle option rather than an equivalent one. It held substantially more weight than stopping, and substantially less than continuing unchanged. Whether that trade-off is worth making, and at what dose, is a clinical decision that depends on why someone wants to reduce in the first place.
Advanced TRT Clinic provides administrative and technology services to a clinical practice that offers paid weight management services. The evidence summarised here points toward continued treatment, which is also what this practice sells. That is a direct commercial interest and readers should weigh this article accordingly. Nothing here is a recommendation to begin, continue, delay or stop any treatment, and there are legitimate reasons to stop that this article does not and cannot evaluate for any individual.
What About Tapering — and What the Evidence Does Not Say
Search results on this topic are full of tapering schedules: step the dose down over a set number of weeks, hold at a low dose, then stop. They are presented with the confidence of established practice.
No randomised trial has compared tapering a GLP-1 receptor agonist with stopping it abruptly. A trial of tapered versus abrupt semaglutide discontinuation is registered and recruiting in a post-bariatric-surgery population, but it has not reported. The specific schedules circulating online are not drawn from trial data.
SURMOUNT-MAINTAIN is sometimes cited as support for tapering, and it is worth being precise about what it tested. It compared staying on a reduced dose indefinitely against stopping — not a stepped withdrawal ending in no treatment. Those are different questions, and the trial answers the first one.
Dose selection, reduction and discontinuation are clinical decisions that depend on your indication, other medications, comorbidities and response. This article deliberately contains no tapering schedule. Adjusting a prescription without the prescriber who issued it also removes the monitoring that would catch problems, and for people taking insulin or a sulfonylurea alongside a GLP-1 receptor agonist, a dose change alters hypoglycemia risk. Speak to your prescriber before changing anything.
What Else Helps, and How Strong That Evidence Is
Several measures are commonly recommended for the period after stopping. They are reasonable, and the honest position is that none has been shown in a randomised trial to prevent regain after GLP-1 withdrawal specifically.
Protecting lean mass. Substantial weight loss includes lean tissue as well as fat, and regained weight tends to return disproportionately as fat. Resistance training and adequate protein intake are the standard approaches to limiting lean mass loss, and a joint advisory from several professional nutrition and obesity societies has drawn attention to nutritional adequacy during this drug class. The mechanistic rationale is sound; the trial evidence that it changes the post-cessation trajectory does not yet exist.
Keeping the structured support in place. In the STEP-1 extension, the lifestyle programme was withdrawn at the same time as the medication, so the trial cannot separate the two effects. That design detail is often overlooked when the result is quoted, and it leaves open the possibility that maintaining structured support matters more than those figures alone suggest.
Monitoring rather than waiting. The regain curve is steepest early. Reviewing weight and metabolic markers in the months after stopping, rather than at an annual visit, is what makes it possible to act while the trajectory is still shallow.
For the fuller picture of how weight changes during treatment, see our guide to the weight loss timeline by week; for the class as a whole, our complete GLP-1 overview.
Before You Stop: What to Discuss
The reason for stopping shapes what the alternatives are. A conversation that starts there tends to be more useful than one that starts with the decision already made.
| Reason for stopping | Worth raising with your clinician |
|---|---|
| Cost or lost coverage | Whether a lower maintenance dose is clinically appropriate, whether a different product with a different coverage pathway applies, and what appeal routes exist |
| Side effects | Whether a dose reduction resolves them, since tolerability often improves at lower doses rather than requiring full withdrawal |
| Goal weight reached | That the trials above tested continuation in exactly this situation, and what the maintenance options are |
| Pregnancy planned | The washout period specified for your product, which is a labelled requirement and not a matter of preference |
| Supply interruption | Options before the gap opens, and why switching to an unapproved or compounded source is not one of them |
Regain is expected and follows a curve. About 60% of lost weight returns within a year, fastest in the first months, then slowing.
Not all of it comes back. The modelled plateau sits at roughly 75% regained, leaving about a quarter of the loss retained.
Dose reduction is a real middle option. In SURMOUNT-MAINTAIN, 5 mg held 16.6% below baseline against 9.9% on placebo.
Tapering schedules are untested. No randomised trial has compared tapering with stopping abruptly.
Safety Information and When to Seek Care
In rodent studies, semaglutide and tirzepatide caused dose-dependent thyroid C-cell tumors. It is unknown whether they cause medullary thyroid carcinoma (MTC) in humans. Both are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other reported risks include pancreatitis, gallbladder disease, diabetic retinopathy complications, acute kidney injury, hypoglycemia when combined with insulin or a sulfonylurea, and gastrointestinal adverse reactions. Report any new neck lump, hoarseness, difficulty swallowing, or severe abdominal pain to a physician immediately.
Seek medical attention without delay for severe abdominal pain, particularly pain radiating to the back; persistent vomiting or an inability to keep fluids down; signs of severe dehydration; yellowing of the skin or eyes; swelling of the face, lips or throat; or difficulty breathing.
If a supply gap is the reason you are stopping, note that medication supplied in a vial with a syringe, or described as compounded, research-grade or not for human use, sits outside the legal supply chain, and dosing errors have been reported with such products. Our guides to tirzepatide side effects and semaglutide for weight management cover what supervised therapy involves.
Get a Physician Evaluation Before Changing Treatment
Advanced TRT Clinic provides administrative and technology services that connect patients with independent licensed clinicians through Beluga Health, P.A., who provide all clinical evaluation, treatment selection, prior authorization support, and ongoing monitoring. Clinicians can assess whether a maintenance dose, a change of product, or discontinuation is appropriate in your case, and what monitoring should accompany it. Advanced TRT Clinic is not a pharmacy, does not fill prescriptions, and is not affiliated with, endorsed by, or a distributor for Novo Nordisk or Eli Lilly. No specific clinical outcome, degree of weight loss, insurance approval, or medication availability is guaranteed. All prescribing decisions are made by independent licensed clinicians based on individual patient assessment, within their scope of practice and applicable state law. Availability varies by state.
